Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
Andrew Mastro discusses various challenges of treating AD in the head-and-neck area, emphasizing the importance in choosing a treatment armed with rapidity, power, and a...
PLAY
Naiem T. Issa, MD, PhD: Mitigating Economic Impacts of Atopic Dermatitis through Effective Treatment
Dr. Issa discusses a real-world study¹ that demonstrated a reduced need for biologic treatments, among other AD treatments, in patients treated with topical ruxolitinib cream,...
PLAY
Dr. Dasilva discusses positive results from a recent study published in the Journal of Clinical and Aesthetic Dermatology that assessed the safety and efficacy of...
PLAY
Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients...
PLAY
Michael Cameron, MD, FAAD: Improving Itch and Quality of Life in Patients with Atopic Dermatitis
Dr. Cameron discusses promising results in a treatment that combined upadacitinib and topical corticosteroids. Reference:
PLAY
James Song, MD: Personalizing Treatment for Atopic Dermatitis
Looking to the future of AD treatment, Dr. Song discusses the unmet need of predicting treatment responses in patients with atopic dermatitis, with the aim...
PLAY